Evidence map›Paper›PMID 35211221›Full record

ArticleCardiology research2022

Healthcare Resource Utilization for Oral Anticoagulant Reversal Therapies in Non-Valvular Atrial Fibrillation/Venous Thromboembolism Patients.

Alex C Spyropoulos, Briain O Hartaigh, Zhun Cao, Craig Lipkin, Scott B Robinson, Harjeet Caberwal, Michaela Petrini, Cheng Wang

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cardiology research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Costs and Healthcare Resource Utilization Associated with Idarucizumab or Andexanet Alfa Oral Anticoagulant Reversal in Patients Hospitalized with Life-Threatening Bleeds.Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Alex C SpyropoulosNorthwell Health, New York, NY, USA.
Briain O HartaighBoehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA.
Zhun CaoPremier, Inc., Charlotte, NC, USA.
Craig LipkinPremier, Inc., Charlotte, NC, USA.
Scott B RobinsonBoehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA.
Harjeet CaberwalBoehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA.
Michaela PetriniBoehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA.
Cheng WangBoehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA.
Boehringer Ingelheim (United States) · USPremier Research Group · USNorthwell Health · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe objective of the study was to describe the healthcare resource utilization (HCRU) and associated costs with hospitalized patients receiving specific versus non-specific oral anticoagulation reversal therapy for life-threatening bleeds and emergency surgeries or urgent procedures.

methodsThis retrospective observational study using the Premier Healthcare Database included adult patients aged ≥ 18 years treated with idarucizumab (IDA) or 3- or 4-factor prothrombin complex concentrates (PCC) to reverse the effects of dabigatran or warfarin, respectively, between October 2015 and February 2018.

resultsMedian ages for IDA (n = 1,232) and PCC (n = 4,939) patients were 78 and 74 years (P < 0.001), respectively. IDA patients had lower bleeding and stroke risk assessment scores (HAS-BLED; P < 0.001 and CHA

conclusionsThis analysis revealed lower HCRU and total hospital costs in patients administered IDA compared with PCC for reversal of oral anticoagulation, though differences in population characteristics and bleeding events were observed that may have contributed to these findings.

Indexed as

AnticoagulationAtrial fibrillationDabigatranHealthcare resource utilization and costsIdarucizumabProthrombin complex concentrateReversal of anticoagulationWarfarin

Identifiers

PMID35211221
PMCPMC8827241
OpenAlexW4214645739

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.